Welcome to our dedicated page for Iovance Biotherapeutics news (Ticker: IOVA), a resource for investors and traders seeking the latest updates and insights on Iovance Biotherapeutics stock.
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) is a clinical-stage biopharmaceutical company dedicated to advancing and commercializing innovative cancer immunotherapies. The company specializes in tumor-infiltrating lymphocyte (TIL) therapies, which harness the body's immune system to target and eliminate cancer cells.
Core Business: Iovance’s primary focus is on developing autologous T-cell therapies designed to treat various solid tumors. Their lead candidate, lifileucel (marketed as AMTAGVI™), has recently gained FDA approval for treating advanced melanoma. This milestone marks it as the first T-cell therapy approved for a solid tumor cancer.
Clinical Trials and Achievements: Lifileucel has shown promise in clinical trials, producing durable responses in patients with metastatic melanoma. Iovance continues to explore its efficacy in other cancers including head and neck carcinoma, cervical cancer, and non-small cell lung cancer through trials like IOV-LUN-202. Preliminary data suggests significant potential benefits, with ongoing responses and durations extending over six months.
Regulatory and Market Footprint: Iovance is preparing for further U.S. regulatory approvals and is working towards global commercialization. The FDA’s recent hold on IOV-LUN-202 due to safety concerns has not affected other trials or the priority review of lifileucel in advanced melanoma.
Manufacturing and Partnerships: With manufacturing facilities like the Iovance Cell Therapy Center (iCTC) and partnerships with entities such as WuXi Advanced Therapies, Iovance is well-equipped to scale production to meet clinical and commercial demands.
Financial Overview: The company reported a net loss of $113.0 million for Q1 2024, reflecting heavy investment in R&D and commercialization efforts. Revenue from Proleukin® sales outside the U.S. contributed $0.7 million, demonstrating ongoing diversification.
Commitment to Innovation: Iovance remains committed to pioneering advancements in cell therapy, including gene-edited approaches, to extend and improve the lives of cancer patients. For more information, please visit www.iovance.com.
Iovance Biotherapeutics (NASDAQ: IOVA) has announced promising clinical data for its tumor-infiltrating lymphocyte (TIL) therapy, showcasing an overall response rate (ORR) of 50% in cervical cancer patients and 87.5% in metastatic melanoma when combined with pembrolizumab. For relapsed non-small cell lung cancer (NSCLC), the TIL therapy demonstrated an ORR of 21.4%. Iovance will present updated results at the upcoming SITC Annual Meeting, signaling a potentially significant step forward in immunotherapy for various cancers.
Iovance Biotherapeutics (NASDAQ: IOVA), a leader in T cell-based cancer therapies, announced its participation in several major conferences in November 2021. Key presentations include:
- Festival of Biologics, Basel: November 9 at 11:10 a.m. ET
- Cowen 5th Annual IO Next Summit: November 15 at 3:45 p.m. ET
- Stifel 2021 Virtual Healthcare Conference: November 17 at 11:20 a.m. ET
- Cell Immunotherapies for Solid Tumors Summit: November 18 at 10:30 a.m. ET
- Piper Sandler 33rd Annual Virtual Healthcare Conference: November 22 at 10:00 a.m. ET
The company focuses on pioneering tumor infiltrating lymphocyte therapies for cancer treatment.
Iovance Biotherapeutics (NASDAQ: IOVA) reported its third quarter 2021 results, showcasing ongoing advancements in T cell-based cancer immunotherapies. The company continues to develop lifileucel, with an expected FDA BLA submission in H1 2022. Iovance received FDA Fast Track designation for lifileucel in combination with pembrolizumab for metastatic melanoma. The cash position stood at $660.8 million, adequate to fund operations into 2023. However, net loss for Q3 was $86.1 million, up from $58.6 million in Q3 2020, raising concerns about increasing R&D and administrative expenses.
Iovance Biotherapeutics (NASDAQ: IOVA) will announce its Q3 financial results on November 4, 2021, followed by a conference call at 4:30 p.m. ET. The company focuses on T cell-based cancer immunotherapies, with its lead candidate, lifileucel, aimed at treating metastatic melanoma. Iovance's TIL platform shows promise across various solid tumors, with ambitions to lead in tumor-infiltrating lymphocyte therapies.
Iovance Biotherapeutics will host a webcast on November 13, 2021 at 5:30 p.m. ET to present updates on its tumor-infiltrating lymphocyte (TIL) therapies in lung cancer and in combination with pembrolizumab. The conference will include insights from key leaders in the field. Additionally, posters will be presented at the SITC Annual Meeting from November 12-14, 2021, detailing phase 2 data for TIL therapy. Iovance aims to pioneer TIL cell therapies, with the potential first one-time cell therapy for solid tumors.
Iovance Biotherapeutics has announced key clinical data presentations at the SITC 36th Annual Meeting on TIL cell therapies for advanced cancers. An oral presentation on November 13 will focus on phase 2 results of TIL in combination with pembrolizumab for immune checkpoint inhibitor-naïve patients. Additionally, posters will cover TIL monotherapy efficacy in NSCLC and advancements in TIL manufacturing. These developments highlight Iovance's commitment to pioneering cancer immunotherapy.
Iovance Biotherapeutics has announced the successful infusion of the first patient with TIL cell therapy LN-145, produced at the Iovance Cell Therapy Center (iCTC). This milestone is part of the IOV-COM-202 study focusing on metastatic non-small cell lung cancer. The state-of-the-art iCTC facility in Philadelphia aims to meet the demand for TIL therapies, with capacity for thousands of patients. The company plans to balance internal and external TIL manufacturing, prioritizing accessibility and cost reduction for its therapies.
Iovance Biotherapeutics reported its second quarter 2021 financial results, highlighting advances in TIL therapy for cancer. The company has a cash position of $708.7 million as of June 30, sufficient to fund operations through 2023. Key clinical data was presented, showing an 86% overall response rate for lifileucel in combination with pembrolizumab for anti-PD-1 naïve melanoma. However, the net loss for Q2 was $81.4 million, an increase from $63 million in Q2 2020, with R&D expenses rising to $62.1 million.
Iovance Biotherapeutics (NASDAQ: IOVA) is set to release its second quarter financial results on August 5, 2021. The company, focused on T cell-based cancer therapies, will also provide a corporate update during a conference call at 4:30 p.m. ET. Iovance's innovative Tumor Infiltrating Lymphocyte (TIL) therapy targets solid tumors and blood cancers, with ongoing studies in metastatic melanoma and cervical cancer. Future clinical studies aim to evaluate TIL in earlier-stage cancers and blood cancers. Key details about the call are accessible on the Iovance website.
FAQ
What is the current stock price of Iovance Biotherapeutics (IOVA)?
What is the market cap of Iovance Biotherapeutics (IOVA)?
What does Iovance Biotherapeutics specialize in?
What is lifileucel, marketed as AMTAGVI™?
What recent regulatory challenges has Iovance faced?
Who are Iovance's key manufacturing partners?
What are the financial highlights for Iovance in Q1 2024?
Which cancers are Iovance's TIL therapies being tested for?
How does Iovance's TIL therapy work?
What is the significance of the FDA approval of AMTAGVI™?
What future plans does Iovance have for lifileucel?
Where can I find more information about Iovance Biotherapeutics?
